In the present study, we investigated whether the expression levels of AK1 could provide prognostic information on AML patients treated with chemotherapy or allogeneic hematopoietic stem cell transplantation (allo-HSCT), independently from a comprehensive panel of other established clinical and molecular predictors. Here, AK1 is linked to acute myeloid leukemia.